Antibody molecules which bind IL-17A and IL-17F
The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
1. A neutralising antibody which binds human IL-17A and human IL-17F comprising a light chain variable domain and a heavy chain variable domain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:7.
2. The neutralising antibody according to claim 1 , wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3.
3. The neutralising antibody according to claim 2 , wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:9.
4. The antibody according to claim 1 , wherein the antibody is a whole antibody or an antigen-binding fragment thereof.
5. The antibody according to claim 4 where the antibody fragment is selected from the group consisting of a Fab, Fab′, F(ab′) 2 , scFv and Fv fragment.
6. The antibody according to claim 1 which also binds the IL-17A/IL-17F heterodimer.
7. The antibody according to claim 1 wherein the antibody is a multi-specific antibody.
8. A neutralising antibody which binds human IL-17A and human IL-17F, comprising a heavy chain comprising the sequence given in SEQ ID NO:15 and a light chain comprising the sequence given in SEQ ID NO:11.
9. A pharmaceutical composition comprising the antibody according to claim 1 or 8 , in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
10. A pharmaceutical composition according to claim 9 , additionally comprising other active ingredients.